Gsk (GSK) Debt to Equity (2016 - 2025)
Gsk (GSK) has 8 years of Debt to Equity data on record, last reported at $1.24 in Q4 2024.
- For Q4 2024, Debt to Equity fell 8.36% year-over-year to $1.24; the TTM value through Dec 2024 reached $1.24, down 8.36%, while the annual FY2024 figure was $1.24, 8.36% down from the prior year.
- Debt to Equity reached $1.24 in Q4 2024 per GSK's latest filing, down from $1.35 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.35 in Q4 2023 and bottomed at $0.37 in Q4 2022.
- Average Debt to Equity over 4 years is $0.88, with a median of $0.91 recorded in 2021.
- Peak YoY movement for Debt to Equity: plummeted 35.61% in 2022, then soared 261.76% in 2023.
- A 4-year view of Debt to Equity shows it stood at $0.58 in 2021, then tumbled by 35.61% to $0.37 in 2022, then skyrocketed by 261.76% to $1.35 in 2023, then dropped by 8.36% to $1.24 in 2024.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $1.24 in Q4 2024, $1.35 in Q4 2023, and $0.37 in Q4 2022.